A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function

Clinical trial NCT04241835 · TERMINATED

Trial details

NCT number: NCT04241835
Sponsor: Epizyme, Inc.
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Hepatic Impairment Advanced Malignant Solid Tumor

Start date: 2020-01-15
Primary completion: 2025-03-12
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.